Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debut

A trio of biotechs priced their IPOs on Thursday into Friday morning, setting the stage for their public trading debuts with more than $850 million combined. Seaport Therapeutics, Hemab Therapeutics and Avalyn Pharma are the ...